Featured Founder
Sarah Boyce
CEO, President
Avidity Biosciences · San Diego, CA
"Our AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics."
About
Avidity Biosciences is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), proud to be the first company to demonstrate the successful targeted delivery of RNA to muscle in clinical trials — a feat previously thought to be unachievable. Avidity has advanced three clinical development programs for three distinct rare muscle diseases: Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD).
Background
Sarah Boyce joined Avidity as President and CEO in October 2019, driving the company's evolution from a research and development entity to a biopharmaceutical company, starting with the company's successful Series C funding round and IPO. Prior to Avidity, she held the position of President and board member of Akcea Therapeutics, and previously held executive roles at Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology, and Roche. She holds a BSc (Hons) in microbiology from the University of Manchester, England, and has been named one of the Fiercest Women in Life Sciences and a Healthcare Technology Report Top 25 Biotech CEO.
Company
Featured Article
Sector
RNA Therapeutics · Rare Disease · Muscle Disease
Stage
STAGE: Nasdaq: RNA (Clinical-Stage, Pre-Commercial)
Location
San Diego, CA
